The TREFOIL Concept 5 Year Clinical Investigation

NCT02940353 | Completed

• 1 other identifier: T-188
• Study Type: interventional
• Target: 110
• Locations: 5 countries
• Sites: 5

Brief Summary

Prospective, single cohort, multi-center study evaluating the TREFOIL concept for the treatment of edentulous or patients with failing mandibular dentition over 5 years. 90 patients (15 per centre) will be included. The subject population is at least 18 years old, in need of an implant restored full prosthesis providing sufficient bone in the interforaminal where a fixed restoration on three implants is regarded as an appropriate treatment solution. The components are TREFOIL treatment concept (implants and framework).

Conditions

Edentulous or Failing Dentition Mandible

Outcome Measures

Primary Outcomes (1)

• Cumulative survival rates for the implants

  5 years

Study Arms (1)

Treatment with Trefoil concept

OTHER

Treatment

Device: TREFOIL concept

Interventions

TREFOIL concept DEVICE

Treatment with Trefoil concept

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Obtained informed consent from the subject.
• The subject is at least 18 years of age (passed cessation of growth) and not older than 80 years.
• The subject is in such a physical and mental condition that a 5-year follow-up period can be carried out without foreseeable problems.
• The subject fulfills the prerequisite that a harmonic, stable occlusal relationship can be achieved with opposing natural teeth resp. fixed or removable opposing dentition (tooth or implant based) or soft tissue born denture.
• The subject is willing and able to comply with all study related procedures (such as exercising oral hygiene and attending all follow-up procedures).
• The subject is compliant with good oral hygiene.
• The subject has an edentulous mandible or failing mandibular dentition providing sufficient bone in the interforaminal where a fixed restoration on three (3) implants is regarded as an appropriate treatment solution.
• The subject has an osseous architecture enough to receive three implants with a length of at least 11.5 mm and a diameter of 5 mm in the interforaminal (e.g. jaw volume B, C or D; inter foramina distance at least 20 mm; buccal/lingual width at least 6-7 mm, vertical height after leveling bone sufficient to receive an implant of at least 11.5 mm length).
• The subject has a jaw curvature that fits to the prefabricated framework design.
• Implants will be placed in healed or extraction sites (clinical stability has to be ensured).
• The implant sites are free from infection and extraction remnants.
• The subjects as well as the implant sites fulfill the criteria for early loading.
• Smokers that have reduced their consumption may be included after a certain test phase (e.g. test phase for reduction from 2 to 1 packages of cigarettes should be at least 6 months).

You may not qualify if:

• After bone leveling sufficient mandible bone volume in the interforaminal present for three (3) implants with a length of at least 11.5 mm and a diameter of 5 mm.
• After bone leveling the jaw curvature does fit to the prefabricated framework.
• The implant sites are free from infection and extraction remnants.
• The subject as well as the implant sites fulfill the criteria for early loading.
• The subject is not able to give her/his informed consent of participating.
• Health conditions, which do not permit the surgical (including anesthesia) or restorative procedure.
• Reason to believe that the treatment might have a negative effect on the subject's overall situation (psychiatric problems), as noted in subject records or history.
• Any disorders in the planned implant area such as previous tumors, chronic bone disease or previous irradiation.
• Alcohol or drug abuse as noted in subject records or in subject history.
• Smoking of more than 1 package of cigarettes per day (\> 20 cigarettes or equivalent).
• Uncontrolled diabetes, i.e. a subject with diagnosed diabetes that has a history of neglecting doctor's recommendations regarding treatment, food and alcohol intake or A1c level above 8%.
• Bisphosphonate therapy - based on individual judgment of the clinician (if intravenously administered or too high oral doses recently before surgery and during follow-up period).
• Pathologic occlusion, e.g. severe bruxism or other destructive habits.
• Lack of opposing dentition or unstable occlusion.
• Ongoing infections, endodontic or periodontal problems in opposing teeth or implants.

Sponsors & Collaborators

• Nobel Biocare: lead

Study Sites (5)

Dr. Higuchi &Skinner

Spokane, Washington, 99216-1077, United States

Location

Branemark Centre

Perth, Western Australia, 6005, Australia

Location

Clinica Rosenberg

Santiago, Santiago de Chile, 10373, Chile

Location

University of Verona

Verona, 37131, Italy

Location

Instituto Davó, Hospital Medimar Internacional

Alicante, 03016, Spain

Location

MeSH Terms

Conditions

Mouth, Edentulous

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases; Tooth Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 19, 2016
• First Posted: October 20, 2016
• Study Start: April 1, 2016
• Primary Completion: June 1, 2022
• Study Completion: June 1, 2022
• Last Updated: March 22, 2023

Record last verified: 2022-09

Locations

AU (1); US (1); IT (1); CL (1); ES (1)